NASDAQ:IBB   ISHARES NASDAQ BIOTECHNOLOGY INDEX FUND
91 0 0
IBB             closed below lower BBs for only the 5th time in the last couple years Friday on some pretty "janky" headlines if you ask me about Henry A. Waxman (D-Beverly Hills) wants Gilead Sciences Inc             . to explain why it priced its new hepatitis C drug, Sovaldi, at $1,000 a pill. Considering nobody asked any questions about the targeted oncology drugs are even more and give people a whole 6-18 weeks efficacy over placebo in a rather miserable existance - seems odd to me the mouse man cares about a relatively effective Hep C drug that more or less cures people. Sometimes sectors that have experienced huge runs by any means necessary sell off but this is some mark ass stuff. Long.
Ideas Scripts Chart
United States
United Kingdom
India
España
Italia
Brasil
Россия
Türkiye
日本
한국
Home Stock Screener Economic Calendar How It Works Chart Features House Rules Moderators For the WEB Widgets Stock Charting Library Priority Support Feature Request Blog & News FAQ Help & Wiki Twitter
Private Messages Chat Ideas Published Followers Following Priority Support Public Profile Profile Settings Billing Sign Out